Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Impetigo is a common, highly infectious skin disease caused by bacterial infection and
characterized by crusting skin lesions. It is most common in children, particularly children
in unhealthy living conditions. In adults, it may follow other skin disorders. Impetigo is
caused primarily by the bacteria Streptococcus pyogenes and/or Staphylococcus aureus, which
can also be isolated from impetigo lesions.
This is a pilot phase II study to evaluate the tolerability and safety and to monitor the
clinical efficacy of Topical Minocycline Foam FXFM244 in impetigo patients.